Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026 (the "Merger Agreement"), by and among Masimo, Danaher Corporation ("Danaher") (NYSE:DHR) and Mobius Merger Sub, Inc. (the "Merger Sub") at Masimo's special meeting of stockholders held virtually on May 1, 2026 (the "Special Meeting").

Under the terms of the Merger Agreement, at the effective time of the merger of Merger Sub with and into Masimo (the "Merger"), each share of common stock issued and outstanding immediately prior to the effective time of the Merger will be canceled and automatically converted into the right to receive $180.00 in cash, without interest.

The Merger is subject to fulfillment of customary conditions to closing, including the receipt of required regulatory approvals and clearances. The Company expects the Merger to close in 2026.